Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Trx Biosciences Limited has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, Olga V Tcherkasskaya. The prosecution is limited to 1 distinct art unit. Olga V Tcherkasskaya is the busiest examiner, responsible for 1 busiest examiner pending action. Since there is only 1 pending office action, this examiner is the sole point of contact for the company's active USPTO matters.
Practitioners should tailor their arguments to the specific expertise of this examiner within the Biotechnology & Pharmaceuticals field, as there are no other distinct art units involved to provide alternative prosecution paths. The 1 pending office action requires a focused response that addresses the technical rejections of Olga V Tcherkasskaya directly. Because the portfolio is concentrated in 1 distinct art unit, the practitioner can assume a consistent application of art unit policies. This 1 busiest examiner pending action is the only active case, which simplifies the management of the Biotechnology & Pharmaceuticals portfolio. A successful resolution with the 1 distinct examiner would result in the clearance of all currently pending actions for the company.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TCHERKASSKAYA, OLGA V | 1 | 55.5% | +46.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18847245 | Compositions Having Improved Bioavailability of Therapeutics and Uses Thereof | TCHERKASSKAYA, OLGA V | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18847245 | Compositions Having Improved Bioavailability of Therapeutics and Uses Thereof | TCHERKASSKAYA, OLGA V | 1615 | §103§112DP | Non-Final OA | — | Pending | Sep 14, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTrx Biosciences Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Olga V Tcherkasskaya has the most, with 1 of Trx Biosciences Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
